ARTICLE | Clinical News

Olaptesed pegol: Interim Phase IIa data

January 13, 2014 8:00 AM UTC

Interim data from a pilot group of 9 evaluable patients with relapsed MM in an open-label, dose-escalation, European Phase IIa trial showed that 1, 2 and 4 mg/kg NOX-A12 in combination with Velcade bortezomib and dexamethasone led to effective and prolonged mobilization of MM cells into the peripheral blood. NOX-A12 led to an ORR of 67%, including a very good partial response rate of 22% and a partial response rate of 44%. The combination was well tolerated. The first 9 patients in the trial received a single dose of 1, 2 or 4 mg/kg NOX-A12 administered 2 weeks before starting combination treatment with NOX-A12, Velcade and dexamethasone. The second part of the trial is evaluating NOX-A12 in combination with Velcade and dexamethasone without the single starting dose of NOX-A12. The trial is enrolling 28 relapsed MM patients. Data were presented at the American Society of Hematology meeting in New Orleans. ...